CAMBRIDGE, MA, September 26, 2016 -- Aurora BioPharma, Inc. will attend Ladenburg Thalmann's 2016 Healthcare Conference Tuesday, September 27th at the Sofitel New York hotel. The day event will feature corporate presentations and pre-scheduled meetings.
Aurora BioPharma is a biotechnology company, revolutionizing the way we will treat cancer in the future. After 50 years of surgery, radiation and chemotherapy, cancer rates are still expected to double in the next 15 years. Medicine has a new weapon, genetically reprogramming the immune system into an elite killer army. Already three companies involved in genetically engineered Chimeric Antigen Receptor (CAR) T therapy, have been awarded Breakthrough Therapy Designation by the FDA for showing up to 90% remissions or nearly a "cure" in leukemia and other liquid tumors. Aurora has shown in a human Phase I/II trial with Glioblastoma, the most lethal brain cancer, nearly double the survival of a $1 Billion drug without the side effects. Glioblastoma claimed the lives of Senator Ted Kennedy and Vice President Biden's son, and many others.
From key executive appointments to vital industry achievements including a place on the Russell 3000 Index to the acquisition of five industry-leading independent broker dealer and advisory firms in under ten years, Ladenburg Thalmann continues to advance strategically to build one of the financial industry's most competitive and sustainable enterprises.
Candace Cobos
Aurora BioPharma, Inc.
Tel: (617) 674-7718 - Fax: (617) 674-7701
candace.cobos@aurora-biopharma.com
SOURCE Aurora BioPharma, Inc.